Scinai Immunotherapeutics Ltd (SCNI)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.05M
Last updated: Nov 17, 2026 at 4:29 PM ET
Scinai Immunotherapeutics Ltd (SCNI) Statistics
Scinai Immunotherapeutics (SCNI) has a market cap of $1.05M. Revenue grew 112.34% over the last 12 months from the 12 months before. It holds $1.05M more cash than debt, 100.27% of its market cap.
Total Valuation
| Market Cap | $1.05M |
|---|---|
| Latest price (Nov 17, 2026) | $0.37 |
Key Dates
| Last Earnings Date | Jul 7, 2026 |
|---|---|
| Fiscal Year End | December |
Price Statistics
The stock is down 96.21% over 52 weeks and trades 64.08% below its 50-day average.
| Beta (1Y) | 1.58 |
|---|---|
| 52-Week Change | -96.21% |
| 1-Month Change | -50.53% |
| 3-Month Change | -86.46% |
| 6-Month Change | -92.70% |
| 5-Year Change | -99.98% |
| 10-Year Change | -99.99% |
| Total Return (1Y) | -96.21% |
| Total Return (3Y CAGR) | -81.93% |
| Total Return (5Y CAGR) | -82.28% |
| Max Drawdown (1Y) | -97.01% |
| Max Drawdown (3Y) | -99.51% |
| Sharpe Ratio (1Y) | -2.48 |
| Correlation with SPY (1Y) | 0.16 |
| 50-Day Average | $1.03 |
| 200-Day Average | $3.91 |
| 52-Week Range | $0.39 to $13.00 |
| RSI (14 Days) | 24.3 |
| Average Volume (20 Days) | 89.86K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 1.23x current liabilities, and total debt is 0.06x shareholder equity.
| Current Ratio | 1.23x |
|---|---|
| Quick Ratio | 1.23x |
| Debt / Equity | 0.06x |
| Interest Coverage | -22.81x |
Returns and Efficiency
Return on invested capital is -61.86% over the last 12 months, against a 5-year average of -39.53%.
| Return on Equity (ROE) | -23.33% |
|---|---|
| Return on Assets (ROA) | -15.93% |
| Return on Invested Capital (ROIC) | -61.86% |
| ROA (5Y Average) | -26.61% |
| ROIC (5Y Average) | -39.53% |
| Asset Turnover | 0.22x |
| Receivables Turnover | 22.11x |
Scores
SCNI has an Altman Z-Score of -12.89, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -12.89 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 2 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue was $3.07M over the last 12 months.
| Revenue | $3.07M |
|---|---|
| Revenue Growth (YoY) | +112.34% |
| Gross Profit | -$3.73M |
| Operating Income | -$8.50M |
| Pretax Income | -$2.50M |
| Net Income | -$2.50M |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 68.22% of the $15.70M in total assets.
| Cash and Equivalents | $1.71M |
|---|---|
| Total Debt | $657.00K |
| Net Cash | $1.05M |
| Working Capital | $443.00K |
| Shareholder Equity | $10.71M |
| Total Assets | $15.70M |
| Total Liabilities | $4.98M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $240.81K of capital spending, operating cash flow left -$7.33M of free cash flow.
| Operating Cash Flow | -$7.09M |
|---|---|
| Capital Expenditures | $240.81K |
| Free Cash Flow | -$7.33M |
| FCF Per Share | -$2.79 |
| Depreciation and Amortization | $1.93M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -276.49%.
| Gross Margin | -121.44% |
|---|---|
| Operating Margin | -276.49% |
| Pretax Margin | -81.34% |
| Net Margin | -81.34% |
| FCF Margin | -238.58% |
Dividends and Yields
SCNI does not pay a dividend. Its free cash flow yield is -8217.58%.
| FCF Yield | -8217.58% |
|---|---|
| Shareholder Yield | 0.00% |
Stock Splits
The last split was a 1-for-10 reverse split on Aug 21, 2026.
| Last Split Date | Aug 21, 2026 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:10 |
Peer Position
Against 6 similar companies, SCNI has the 4th highest ROIC.
ROICPeer median -91.59%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -100.00%
| ROIC | -61.86% vs -91.59% median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | +112.34% vs -100.00% median |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About SCNI
What is SCNI's market cap?
Scinai Immunotherapeutics has a market cap of $1.05M.
How many shares of SCNI are outstanding?
Scinai Immunotherapeutics has 240.53K shares outstanding.
Does SCNI pay a dividend?
No. Scinai Immunotherapeutics does not pay a dividend.
How much debt does SCNI have?
Scinai Immunotherapeutics has $657.00K of total debt and $1.71M of cash and equivalents, a net cash position of $1.05M.
SCNI pages: Overview, Charting, Earnings, Financials, Statistics, Competitors